Alvotech And Fuji Further Expand Biosimilars Partnership

Alvotech has extended the potential reach of its biosimilars in Japan by adding a further early-stage candidate to an existing commercialization deal with Fuji Pharma, taking the alliance to six biosimilars overall.

While Alvotech and Fuji did not reveal specifics of the latest addition, the deal – first struck in late 2018, shortly after Fuji invested $50m in Alvotech (Also see "Alvotech hands Fuji rights to Japan lines" - Generics Bulletin, 23 November, 2018.) – was already known to cover ustekinumab since an update in mid-2019. (Also see "Alvotech And Fuji Stretch Alliance To Ustekinumab In Japan" - Generics Bulletin, 30 April, 2019